Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Rhea-AI Summary
Glucotrack (Nasdaq:GCTK) reported first quarter 2026 results and progress on its fully implantable continuous blood glucose monitoring (CBGM) program.
Key updates include FDA IDE submission for a U.S. clinical study targeted for 2H 2026, supportive peer-reviewed data, debt reduction, and lower net loss year-over-year.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Submitted FDA IDE for U.S. clinical study of fully implantable CBGM, targeting 2H 2026 start
- Peer-reviewed data showed 6.8% MARD and 240-day sensor stability in ovine CBGM study
- Reduced $3.6 million promissory note balance to approximately $1.6 million
- Net loss decreased to $4.3 million from $6.8 million year-over-year
- Other expense declined to $0.1 million from $3.3 million year-over-year
- Equity line draw of approximately $1.0 million post-quarter strengthened liquidity
Negative
- Research and development expenses increased to $2.1 million from $1.9 million
- General and administrative expenses rose to $2.1 million from $1.6 million
- Cash and cash equivalents declined to $3.9 million from $7.4 million since year-end
- Company expects existing cash to fund operations only into early third quarter 2026
News Market Reaction – GCTK
On the day this news was published, GCTK declined 2.97%, reflecting a moderate negative market reaction. Argus tracked a trough of -7.5% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $42K from the company's valuation, bringing the market cap to $1.36M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | FY 2025 earnings | Positive | -14.1% | Reported 2025 results, new patents, cash of $7.4M, and IDE plan. |
| Nov 13 | Q3 2025 earnings | Positive | -8.6% | Secured new financing, higher cash, and outlined IDE and trial plans. |
| Aug 14 | Q2 2025 earnings | Positive | +0.9% | Detailed Australia feasibility study, strong MARD data, and $9.6M cash. |
| May 14 | Q1 2025 earnings | Neutral | +0.1% | Advanced CBGM plans with higher net loss and a stronger cash position. |
| Mar 31 | FY 2024 earnings | Positive | +28.9% | First human CBGM study success, higher R&D and losses, and $5.6M cash. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases often came with sizable price swings, frequently negative despite generally constructive operational updates, suggesting a history of volatile and sometimes contrarian reactions around results.
Over the last year, Glucotrack’s earnings updates have mixed financing steps, CBGM development progress, and growing losses. In 2024, the company transitioned to clinical stage with a first human CBGM study and raised $16.3M, yet shares jumped only around some reports. Subsequent quarters in 2025 highlighted new studies, added advisors, and cash balances between roughly $5.6M–$9.6M, but several earnings days saw notable declines. Today’s Q1 2026 release continues that pattern of operational progress alongside ongoing losses and financing dependence.
Key Terms
investigational device exemption (ide) regulatory
u.s. food and drug administration (fda) regulatory
continuous blood glucose monitoring (cbgm) medical
mean absolute relative difference (mard) medical
promissory note financial
equity line of credit financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology
Company targeting U.S. clinical trial launch in second half of 2026
Peer-Reviewed Studies published in The Journal of Diabetes Research and in the Institute of Electrical and Electronics Engineers (IEEE) Sensors Journal support advancement of Company’s implantable CBGM technology
Rutherford, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2026.
“During the quarter, we made meaningful progress advancing our CBGM program while further strengthening our foundation as a company,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “We successfully completed our presub process with FDA, culminating in the submission of our IDE to the FDA, an important milestone that brings us closer to initiating U.S. clinical studies. We also published two key sets of preclinical and in-vitro data in peer-reviewed journals, further supporting the development of our technology, and strengthened our balance sheet by reducing debt and extending our financial runway.”
First Quarter 2026 & Recent Highlights
Corporate Highlights
- The Company held its third Patient Advisory Board (PAB) meeting during which patients shared perspectives on diabetes device prescribing and initiation, as well as their experiences with healthcare provider education and preparedness.
- Strengthened balance sheet with debt reduction. The Company reduced the outstanding balance of its
$3.6 million promissory note to approximately$1.6 million , primarily through the exchange of a portion of the note into shares of common stock at market price. Subsequent to quarter end, the Company drew approximately$1.0 million under its existing equity line of credit facility, further strengthening its cash position.
Advanced Product and Clinical Development
- The Company successfully submitted its IDE application to the FDA to initiate a U.S. clinical study for its fully implantable CBGM technology. The submission represents a key milestone in advancing the Company's CBGM technology into U.S. clinical evaluation, supported by several years of focused engineering, preclinical evaluation, and iterative design work.
- In a peer-reviewed article titled, “Year-Long Measurement of Glucose Oxidase Deactivation in Electrochemical Glucose Sensors,” published in the IEEE Sensors Journal, the Company reported data validating the long-term stability of its glucose oxidase sensor, providing foundational scientific evidence to support the device’s intended three-year longevity.
- In a peer-reviewed article titled, “In Vivo Evaluation of a Novel Long-Term Intravascular Implantable Continuous Blood Glucose Monitor in an Ovine Model: A Glucotrack Inc. Investigation,” published in The Journal of Diabetes Research, the Company reported data demonstrating the long-term accuracy and stability of the Company’s fully implantable CBGM system. The in-vivo ovine study showed a
6.8% Mean Absolute Relative Difference (MARD) and sustained sensor performance over 240 days, supporting the platform’s progression toward clinical studies.
Anticipated Milestones
- Initiate U.S. clinical study of the Company’s CBGM in 2H 2026.
- Present clinical data demonstrating the safety and accuracy of the CBGM technology at additional industry conferences, with timing and venues to be determined as data become available.
- Continue to gain insight from patients living with diabetes on current management challenges and receive feedback on Glucotrack’s product development and commercialization strategies through additional PAB meetings.
Financial Results for the Quarter ended March 31, 2026
Research and Development Expenses: Research and development expenses were
General and Administrative Expenses: General and Administrative expenses were
Other (Income) Expense, Net: Other expense was
Net Loss: Net loss for the first quarter of 2026 was
Cash Position: Cash and cash equivalents as of March 31, 2026, were
Based on current plans and assumptions, the Company believes that its existing cash and cash equivalents will provide sufficient runway into early 3Q 2026, allowing for the initiation of its U.S. human clinical trial shortly thereafter.
The Glucotrack Continuous Blood Glucose Monitor is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information about Glucotrack’s CBGM, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.
Contacts:
| Investor Relations: | Media: |
| investors@glucotrack.com | GlucotrackPR@icrinc.com |
GLUCOTRACK INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands of US dollars except share data)
| In thousands of US dollars (except stock data) | ||||||||
| March 31, 2026 | December 31, 2025 | |||||||
| Unaudited | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 3,929 | $ | 7,383 | ||||
| Other current assets | 285 | 284 | ||||||
| Total current assets | 4,214 | 7,667 | ||||||
| Operating lease right-of-use asset, net | 26 | 33 | ||||||
| Property and equipment, net | 116 | 138 | ||||||
| TOTAL ASSETS | $ | 4,356 | $ | 7,838 | ||||
| LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | $ | 1,299 | $ | 1,317 | ||||
| Operating lease liability, current | 26 | 28 | ||||||
| Promissory notes | 3,330 | 3,182 | ||||||
| Other current liabilities | 320 | 246 | ||||||
| Total current liabilities | 4,975 | 4,773 | ||||||
| Non-Current Liabilities | ||||||||
| Derivative financial liabilities | - | 1 | ||||||
| Operating lease liability, non-current | - | 5 | ||||||
| Loans from stockholders | 232 | 231 | ||||||
| Total liabilities | 5,207 | 5,010 | ||||||
| Commitments and contingent liabilities (Note 5) | ||||||||
| Stockholders’ Equity (Deficit) | ||||||||
| Common Stock of | ||||||||
| 250,000,000 shares authorized as of March 31, 2026 and as of December 31, 2025; 2,524,279 and 910,688 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 3 | 1 | ||||||
| Additional paid-in capital | 155,274 | 151,080 | ||||||
| Receipts on account of shares | - | 3,544 | ||||||
| Accumulated other comprehensive income | 44 | 41 | ||||||
| Accumulated deficit | (156,172 | ) | (151,838 | ) | ||||
| Total stockholders’ equity (deficit) | (851 | ) | 2,828 | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $ | 4,356 | $ | 7,838 | ||||
GLUCOTRACK INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands of US dollars except share data) (unaudited)
| Three-month period ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 2,132 | $ | 1,871 | ||||
| General and administrative | 2,071 | 1,627 | ||||||
| Total operating expenses | 4,203 | 3,498 | ||||||
| Loss from operations | 4,203 | 3,498 | ||||||
| Other (income) expense: | ||||||||
| Change in fair value of derivative liabilities | (1 | ) | 3,376 | |||||
| Other (income) expense, net | 132 | (4 | ) | |||||
| Finance expenses (income), net | - | (37 | ) | |||||
| Total other (income) expense | 131 | 3,335 | ||||||
| Net Loss | 4,334 | 6,833 | ||||||
| Other comprehensive income: | ||||||||
| Foreign currency translation adjustment | (3 | ) | (36 | ) | ||||
| Comprehensive loss for the period | $ | 4,331 | $ | 6,797 | ||||
| Basic and diluted loss per share | $ | 2.65 | $ | 40.14 | ||||
| Weighted average number of Common Stock outstanding used in computing basic and diluted loss per share | 1,638,128 | 169,345 | ||||||
